What this Trial Is About

Researchers are studying how genetic and epigenetic factors affect the response to selective serotonin reuptake inhibitors (SSRIs) in people with obsessive-compulsive disorder (OCD). The goal is to predict SSRI treatment response before the drug effects appear, tracking changes up to 4 months, 6 months, and 1 year after starting medication. This study involves individuals aged 19 to 70 who have OCD and are either new to treatment or have not taken related drugs for over 3 months. Participants will receive SSRIs at usual doses for OCD, such as fluoxetine ranging from 40 to 80 mg equivalent doses. The specific SSRI type and dosage will depend on each participant's condition, following standard clinical guidelines. Blood samples will be collected to analyze DNA, proteins, and microbiome markers. Some participants will also undergo resting state functional MRI scans to support the research. Throughout the study, participants will be assessed at baseline, 4 months, 6 months, and 1 year using multiple scales measuring OCD severity, depression, anxiety, impulsiveness, perfectionism, trauma history, and other psychological factors. The main outcome is the change in OCD symptoms measured by the Yale-Brown Obsessive-Compulsive Scale over time. This comprehensive evaluation aims to understand how biological markers relate to treatment response and symptom changes in OCD.

Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder